Resources
8 Results (showing 1 - 8)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/21/2019 (updated 3/28/2024)
This report was developed as part of an initiative of the U.S. Department of Health and Human Services (HHS) Office on Women’s Health (OWH) to examine prevention, treatment, and recovery issues for women who misuse opioids, have opioid use disorders (OUDs), and/or overdose on opioids.
Posted 6/2/2020 (updated 3/28/2024)
We know from RCORP grantees, first responders, hospitals, people who use drugs, the media and other allies that many communities are seeing spikes in overdose (OD) events and deaths since the onset of COVID-19. Sometimes these deaths come at alarming levels because of stretched public health infrastructure and the time it takes to turn around data. The webinar took place on May 26, 2020.
Posted 12/29/2020 (updated 4/4/2024)
An analysis of emergency department data shows a rise in nonfatal drug overdoses for youth under 15, from 2016 to 2019. Overdoses among the youngest kids aged 0-14 are relatively rate. However, risk increases with age, as the rate of all drug overdoses among youth aged 15-24 was more than double that of 11-14-year olds. Stimulant overdoses increased for all age groups, while heroin decreased for 15-24-year olds.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/14/2021 (updated 4/3/2024)
Participants learned evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters discussed methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Robert Childs, MPH, JBS International
Christine Rodriguez, MPH, Vital Strategies
Posted 3/9/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) together with leading clinicians, researchers, and policy experts led the development of a standard clinical definition for opioid withdrawal in infants to help improve care. It is accompanied with a set of foundational principles that outlines bioethical uses for the definition, distinctly centering around identifying clinical and supportive care needs of mothers and their infants, using an evidence-based, compassionate, and equitable approach.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.